Research programme: therapeutic agents - Pharmacopeia/Schering-Plough

Drug Profile

Research programme: therapeutic agents - Pharmacopeia/Schering-Plough

Alternative Names: PS 015146; PS 241541

Latest Information Update: 11 Feb 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Pharmacopeia; Schering-Plough
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Cancer; Inflammation; Metabolic disorders; Respiratory tract disorders; Unspecified

Most Recent Events

  • 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
  • 19 Apr 2007 Another candidate has been selected by Schering-Plough for preclinical development
  • 17 Apr 2007 Preclinical trials in Undefined indication in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top